GSA Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $406K | Sell |
12,162
-14,967
| -55% | -$372K | 0.03% | 1137 |
|
|
2026
Q1 | $568K | Buy |
+27,129
| New | +$611K | 0.04% | 833 |
|
|
2025
Q4 | – | Sell |
-22,723
| Closed | -$684K | – | 2011 |
|
|
2025
Q3 | $684K | Buy |
+22,723
| New | +$681K | 0.06% | 644 |
|
|
2025
Q2 | – | Sell |
-43,274
| Closed | -$1.57M | – | 2084 |
|
|
2025
Q1 | $1.57M | Buy |
+43,274
| New | +$1.8M | 0.14% | 146 |
|
|
2024
Q4 | – | Sell |
-11,508
| Closed | -$639K | – | 1956 |
|
|
2024
Q3 | $639K | Sell |
11,508
-4,067
| -26% | -$207K | 0.05% | 755 |
|
|
2024
Q2 | $640K | Buy |
15,575
+5,026
| +48% | +$215K | 0.04% | 804 |
|
|
2024
Q1 | $493K | Buy |
+10,549
| New | +$498K | 0.04% | 892 |
|
|
2023
Q2 | – | Sell |
-27,326
| Closed | -$1.1M | – | 1870 |
|
|
2023
Q1 | $1.1M | Buy |
+27,326
| New | +$1.17M | 0.11% | 268 |
|
|
2022
Q4 | – | Sell |
-10,560
| Closed | -$437K | – | 1812 |
|
|
2022
Q3 | $437K | Buy |
+10,560
| New | +$543K | 0.06% | 676 |
|
|
2022
Q2 | – | Sell |
-17,345
| Closed | -$1.26M | – | 1730 |
|
|
2022
Q1 | $1.26M | Sell |
17,345
-3,605
| -17% | -$251K | 0.17% | 110 |
|
|
2021
Q4 | $1.76M | Buy |
+20,950
| New | +$1.7M | 0.22% | 40 |
|
|
2021
Q1 | – | Sell |
-3,084
| Closed | -$427K | – | 1415 |
|
|
2020
Q4 | $427K | Buy |
+3,084
| New | +$366K | 0.07% | 521 |
|
|
2020
Q1 | – | Sell |
-10,129
| Closed | -$433K | – | 1466 |
|
|
2019
Q4 | $433K | Buy |
10,129
+2,170
| +27% | +$89.5K | 0.05% | 762 |
|
|
2019
Q3 | $340K | Buy |
+7,959
| New | +$432K | 0.05% | 802 |
|
|
2019
Q2 | – | Sell |
-2,900
| Closed | -$201K | – | 1685 |
|
|
2019
Q1 | $201K | Buy |
+2,900
| New | +$166K | 0.02% | 1237 |
|
|
2018
Q3 | – | Sell |
-10,582
| Closed | -$813K | – | 1844 |
|
|
2018
Q2 | $813K | Sell |
10,582
-7,018
| -40% | -$453K | 0.04% | 878 |
|
|
2018
Q1 | $897K | Buy |
+17,600
| New | +$886K | 0.05% | 734 |
|
|
2016
Q1 | – | Sell |
-11,188
| Closed | -$1.25M | – | 1877 |
|
|
2015
Q4 | $1.25M | Buy |
11,188
+1,218
| +12% | +$122K | 0.06% | 533 |
|
|
2015
Q3 | $960K | Buy |
9,970
+1,170
| +13% | +$134K | 0.05% | 669 |
|
|
2015
Q2 | $901K | Buy |
8,800
+3,700
| +73% | +$287K | 0.03% | 985 |
|
|
2015
Q1 | $317K | Sell |
5,100
-5,648
| -53% | -$314K | 0.01% | 1683 |
|
|
2014
Q4 | $472K | Buy |
+10,748
| New | +$492K | 0.03% | 963 |
|
Other funds holding RARE
RI
FCM
GSA Capital Partners's RARE Position: Q2 2026 in Review
GSA Capital Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 55% in Q2 2026, selling an estimated $372K and leaving 12,162 shares worth $406K. The position accounts for 0.03% of the portfolio, ranked #1137.
GSA Capital Partners first reported a position in RARE in Q4 2014 and has held it in 22 quarters since. The position peaked at $1.76M in Q4 2021. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- GSA Capital Partners held 12,162 shares of Ultragenyx Pharmaceutical worth $406K as of Q2 2026.
- GSA Capital Partners sold 14,967 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $372K.
- Ultragenyx Pharmaceutical made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1137 holding.
- GSA Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 22 quarters since.
- GSA Capital Partners's Ultragenyx Pharmaceutical position peaked at $1.76M in Q4 2021.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.